share_log

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

b. Riley Securities维持对Bicycle Therapeutics的中立评级,将目标价下调至17美元
Benzinga ·  12/13 17:38  · 评级/大行评级

B. Riley Securities analyst Kalpit Patel maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Neutral and lowers the price target from $28 to $17.

b. Riley Securities 分析师 Kalpit Patel 维持 Bicycle Therapeutics (纳斯达克:BCYC) 的中立评级,并将目标价从28美元下调至17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发